Advertisement

European Child & Adolescent Psychiatry

, Volume 21, Issue 4, pp 237–238 | Cite as

Would some cannabinoids ameliorate symptoms of autism?

  • Rami Bou Khalil
Letter to the Editor

Dear Sir,

There has been a massive growth of public awareness and research funding around autism spectrum disorders (ASD) over the past 10 years. This disorder is one of the groups of neurodevelopmental disorders known as pervasive developmental disorders characterized by three core deficits: impaired communication, impaired reciprocal social interaction and restricted, repetitive and stereotyped patterns of behaviors or interests. At present, there is no psychopharmacologic treatment for the core symptoms of autism.

In addition to their classic physiologic functions in diuresis, parturition and lactation, oxytocin and vasopressin act as important modulators of social cognition and behaviors in a diverse range of species including humans [1]. Some clinical studies have provided a body of evidence that raises optimism for the feasibility of oxytocin-based therapeutics in ASD. For example, administration of oxytocin to patients with ASD has been shown to facilitate processing of social...

Keywords

Autism Spectrum Disorder Autism Spectrum Disorder Vasopressin Oxytocin Dorsal Root Ganglion Neuron 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Meyer-Lindenberg A, Domes G, Kirsch P, Heinrichs M (2011) Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nat Rev Neurosci 12:524–538PubMedCrossRefGoogle Scholar
  2. 2.
    Green JJ, Hollander E (2010) Autism and oxytocin: new developments in translational approaches to therapeutics. Neurotherapeutics 7:250–257PubMedCrossRefGoogle Scholar
  3. 3.
    Andari E, Duhamel JR, Zalla T, Herbrecht E, Leboyer M, Sirigu A (2010) Promoting social behavior with oxytocin in high-functioning autism spectrum disorders. Proc Natl Acad Sci USA 107:4389–4394PubMedCrossRefGoogle Scholar
  4. 4.
    Sala M, Braida D, Lentini D et al (2011) Pharmacologic rescue of impaired cognitive flexibility, social deficits, increased aggression, and seizure susceptibility in oxytocin receptor null mice: a neurobehavioral model of autism. Biol Psychiatry 69:875–882PubMedCrossRefGoogle Scholar
  5. 5.
    Wainwright A, Rutter AR, Seabrook GR, Reilly K, Olivier KR (2004) Discrete expression of TRPV2 within the hypothalamo-neurohypophysial system: implications for regulatory activity within the hypothalamic–pituitary–adrenal axis. J Comp Neurol 474:24–42PubMedCrossRefGoogle Scholar
  6. 6.
    Caterina MJ, Leffler A, Malmberg AB, Martin WJ, Trafton J, Peterson-Zeitz KR (2000) Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 288:306–313PubMedCrossRefGoogle Scholar
  7. 7.
    Qin N, Neeper MP, Liu Y, Hutchinson TL, Lubin ML, Flores CM (2008) TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. J Neurosci 28:6231–6238PubMedCrossRefGoogle Scholar
  8. 8.
    Scuderi C, Filippis DD, Iuvone T, Blasio A, Steardo A, Esposito G (2009) Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders. Phytother Res 23:597–602PubMedCrossRefGoogle Scholar
  9. 9.
    Onaivi ES, Benno R, Halpern T et al (2011) Consequences of cannabinoid and monoaminergic system disruption in a mouse model of autism spectrum disorders. Curr Neuropharmacol 9:209–214PubMedCrossRefGoogle Scholar
  10. 10.
    Belzung C, Leman S, Vourc’h P, Andres C (2005) Rodents model for autism: a critical review. Drug Discov Today Dis Models 2:93–101CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  1. 1.Psychiatric Hospital of the CrossJalledibLebanon
  2. 2.Saint Joseph UniversityBeirutLebanon

Personalised recommendations